• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CenterWatch Monthly January 2009

CenterWatch Monthly January 2009

January 7, 2009
CenterWatch Staff

Japan’s Global Clinical Trials Initiations Skyrocket

New global clinical trial initiations increased dramatically from 2006 to 2007 in Japan. No other country in Asia experienced anywhere near such an increase in new global clinical trial initiations. Though Japan has made great strides at every level—government, site, sponsor, CRO and patient—to become more attractive for global clinical trial initiation, the country’s work is far from over. In fact, it is just beginning.

2008: Strong Start, Tough Finish

2008 began with high expectations for growth in the clinical trial space, but difficult economic conditions led many companies to slow non-organic growth and cut costs. In spite of the challenges brought on by the economic and regulatory climate—or perhaps because of them—some emerging markets within the industry thrived. Companies faced heightened transparency and disclosure requirements as regulators, congressional investigators, the media and even patients increased their scrutiny of drug development practices.

ICH E9 a Decade Later—What’s Working, What’s Not

Experts are divided as to whether the original guideline International Conference on Harmonisation (ICH) E9, adopted in February 1998, needs further revision. The harmonized biostatistical tool that describes essential considerations for the design and analysis of clinical trials—especially the confirmatory, or hypothesis-testing, trials that are the basis for demonstrating effectiveness—is considered by the majority of statistical experts to be as relevant today as it was a decade ago. However, experts agree that more needs to be done to codify agreement on controversial subjects such as adaptive designs, missing data imputation methods, and dynamic allocation.

Eye On: Adverse Effects of Chemotherapy

Although many currently available chemotherapeutic agents are effective in prolonging survival in cancer patients, they often do so at the risk of poor tolerability and toxicity. Acute complications may include chemotherapy-related nausea or vomiting (CINV), diarrhea and mucositis, whereas chronic complications may include neutropenia or anemia due to bone marrow suppression, or nerve damage manifest as hearing loss or neuropathy.

To read the full articles for this issue or for more information on these and other breaking stories, please click here for subscription information.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing